BiomX, Inc.

Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024, which is being held from 27-30 April 2024, in Barcelona, Spain. The abstract submitted by the Company was selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024. Details of the presentation: Title:Chronic Pseudomonas aeruginosa pulmonary infection treated with a nebulised phage cocktail in patients with cystic fibrosis: a phase 1b/2a randomised, double-blind, placebo-controlled, multicentre studyPoster number:P2546Session type:Poster SessionSession title:5c. New or repurposed antibacterial agents: clinical studies and randomized trialsSession date:April 28, 2024Session time/location:12:00-13:30 CEST in Poster AreaPresenter:Urania Rappo, MD, BiomX Inc., Cambridge, MA, United StatesThe poster will also be made available as an ePoster for viewing by delegates on the ECCMID virtual platform during ECCMID 2024 and in the publications section of the BiomX website. About BX004BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of cystic fibrosis (“CF”) patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial where BX004 demonstrated improvement in pulmonary function associated with a reduction in P. aeruginosa burden compared to placebo in a predefined subgroup of patients with reduced lung function1. BiomX expects to initiate a randomized, double blind, placebo-controlled, multi-center Phase 2b trial in CF patients with chronic P. aeruginosa pulmonary infections in the fourth quarter of 2024. The trial is designed to enroll approximately 60 patients randomized in a 2:1 ratio to BX004 or placebo. Treatment is expected to be administered via inhalation twice daily for a duration of 8 weeks. The trial is designed to demonstrate microbiologic reduction of P. aeruginosa burden in sputum and evaluate clinical parameters such as lung function measured by FEV1 and patient reported outcomes, as well as monitor the safety and tolerability of BX004. Trial results are expected in the third quarter 2025. The Food and Drug Administration (“FDA”) has granted BX004 Fast Track designation and Orphan Drug Designation. About BiomXBiomX is a clinical-stage company developing both natural and engineered phage cocktails and personalized phage treatments designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release. Safe HarborThis press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses the expected timing of clinical trials, key data readouts and topline results and the potential benefits of BX004, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. In addition, past and current pre-clinical and clinical results, as well as compassionate use, are not indicative and do not guarantee future success of BiomX clinical trials. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements, as a result of various important factors, including risks and uncertainties related to the ability to recognize the anticipated benefits of the acquisition of Adaptive Phage Therapeutics, Inc.; the outcome of any legal proceedings that may be instituted against BiomX following the acquisition and related transactions; the ability to obtain or maintain the listing of the common stock of BiomX on the NYSE American following the acquisition; costs related to the acquisition; changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to our development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 4, 2024, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements. BiomX ContactsInvestor Relations:LifeSci Advisors, LLCJohn FrauncesManaging Director(917) 355-2395jfraunces@lifesciadvisors.com, orBrian MullenLifeSci Advisors, LLC(203) 461-1175Bmullen@lifesciadvisors.com BiomX, Inc.Assaf OronChief Business Officerassafo@biomx.com Source: BiomX Inc.

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) --BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024, which is being held from 27-30 April 2024, in Barcelona, Spain. The abstract submitted by the Company was selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024. Details of the presentation: Title: Chronic Pseudomonas aeruginosa pulmonary infection treated with a nebulised phage cocktail in patients with cystic fibrosis: a phase 1b/2a randomised, double-blind, placebo-controlled, multicentre study Poster number: P2546 Session type: Poster Session Session title: 5c. New or repurposed antibacterial agents: clinical studies and randomized trials Session date: April 28, 2024 Session time/location: 12:00-13:30 CEST in Poster Area Presenter: Urania Rappo, MD, BiomX Inc., Cambridge, MA, United States The poster will also be made available as an ePoster for viewing by delegates on the ECCMID virtual platform during ECCMID 2024 and in the publications section of the BiomX website. About BX004 BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of cystic fibrosis (“CF”) patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial where BX004 demonstrated improvement in pulmonary function associated with a reduction in P. aeruginosa burden compared to placebo in a predefined subgroup of patients with reduced lung function1. BiomX expects to initiate a randomized, double blind, placebo-controlled, multi-center Phase 2b trial in CF patients with chronic P. aeruginosa pulmonary infections in the fourth quarter of 2024. The trial is designed to enroll approximately 60 patients randomized in a 2:1 ratio to BX004 or placebo. Treatment is expected to be administered via inhalation twice daily for a duration of 8 weeks. The trial is designed to demonstrate microbiologic reduction of P. aeruginosa burden in sputum and evaluate clinical parameters such as lung function measured by FEV1 and patient reported outcomes, as well as monitor the safety and tolerability of BX004. Trial results are expected in the third quarter 2025. The Food and Drug Administration (“FDA”) has granted BX004 Fast Track designation and Orphan Drug Designation. About BiomX BiomX is a clinical-stage company developing both natural and engineered phage cocktails and personalized phage treatments designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit , the content of which does not form a part of this press release. Safe Harbor This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses the expected timing of clinical trials, key data readouts and topline results and the potential benefits of BX004, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. In addition, past and current pre-clinical and clinical results, as well as compassionate use, are not indicative and do not guarantee future success of BiomX clinical trials. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements, as a result of various important factors, including risks and uncertainties related to the ability to recognize the anticipated benefits of the acquisition of Adaptive Phage Therapeutics, Inc.; the outcome of any legal proceedings that may be instituted against BiomX following the acquisition and related transactions; the ability to obtain or maintain the listing of the common stock of BiomX on the NYSE American following the acquisition; costs related to the acquisition; changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to our development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 4, 2024, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements. BiomX Contacts Investor Relations: LifeSci Advisors, LLC John Fraunces Managing Director (917) 355-2395 jfraunces@lifesciadvisors.com, or Brian Mullen LifeSci Advisors, LLC (203) 461-1175 Bmullen@lifesciadvisors.com BiomX, Inc. Assaf Oron Chief Business Officer assafo@biomx.com Source: BiomX Inc.

More than 1,000 clinical trials for acute myeloid leukemia drugs have been launched globally since 2019, a new report said. Europe has launched the most clinical trials for cystic fibrosis (CF) treatments, while North America leads in those for acute myeloid leukemia (AML), according to a pair of new global trial landscape reports announced April 10 by contract research organization Novotech. Global venture funding for R&D on treatments for both diseases topped $1 billion each over the past five years.  CF is caused by an inherited mutation in the gene CFTR that damages mucus-producing cells in the lungs, pancreas and other organs. Though there is currently no cure, the past four decades have seen significant progress on treatments. Before the 1980s, half of CF patients survived into their 20s, the Novotech report noted. By 2025, 75% of patients with CF are expected to live to adulthood. Drugmakers since 2018 have launched 450 clinical trials for CF drugs worldwide, with 37% in Europe and 35% in North America, the report said. The field includes Vertex Pharmaceuticals, the creator of a powerful but pricey drug trio called Trikafta that in 2019 became the first FDA-approved triple combination therapy for the most common genetic mutation in CF. The company has several investigational CF treatments currently in late-stage clinical trials on top of four therapies already on the market.  Worldwide venture capital funding for CF research totaled just over $1 billion between 2019 and 2023, the report said, with the U.S. leading at $919 million followed by the Netherlands, Israel and Italy. ReCode Therapeutics, Adaptive Phage Therapeutics, Metagenomi and Carmine collected the most VC dollars. ReCode, Metagenomi and Carmine are all working on genetic medicines, while Adaptive Phage (recently acquired by BiomX) is studying whether viruses called bacteriophages can clear dangerous bacteria from the lungs of those with CF.  Another Novotech report highlights the landscape for AML, a type of blood cancer that begins in the blood stem cells in the bone marrow. It’s the second most prevalent blood cancer in adults and children but has the lowest survival rate. Fewer than half of patients live beyond five years of diagnosis. Pharma companies have attempted to improve the odds by launching more than 1,000 trials for AML treatments globally since 2019, according to Novotech. North American trials account for about 40% of those trials, with another third in the Asia-Pacific region and 22% in Europe. Venture funding for AML R&D from U.S. firms totaled about $1.8 billion between 2019 and 2023, with another $1.2 billion in China over the same period. The top-funded companies for AML drugs within the same time span were Opna Bio, Shorla Oncology and OncoVerity.  Novotech runs clinical trials for clients in the APAC region, the U.S. and Europe. The CRO is based in Australia and has more than 3,000 staff worldwide, according to the company.